Appendix 5: Trials investigating nicotine inhaler, nicotine nasal spray, and nicotine tablet (page 1 of 2)

Study	Sample size	Design	Country	Mean CPD	Smoking abstinence (%)							
					6 Months				12 Months			
					Point prevalence		Continuous		Point prevalence		Continuous	
					Active	Control	Active	Control	Active	Control	Active	Control
Nicotine Inhaler												
Tonnesen 1993[1]	286	R, DB, PC	Denmark	20	NR	NR	17	8	NR	NR	15	5
Hjalmarson 1997[2]	247	R, DB, PC	Sweden	21	NR	NR	35	19	31	19	28	18
Schneider 1996[3]	223	R, DB, PC	USA	28	NR	NR	17	9	NR	NR	13	8
Leischow 1996[4]	222	R, DB, PC	USA	26	NR	NR	20	6	NR	NR	11	5
Nicotine Nasal Spray												
Schneider 1995[5]	255	R, DB, PC	USA	29	NR	NR	25	10	NR	NR	18	8
Hjalmarson 1994[6]	248	R, DB, PC	Sweden	21	NR	NR	35	15	NR	NR	27	15
Sutherland 1992[7]	227	R, DB, PC	England	26	NR	NR	32	12	NR	NR	26	10
Blondal 1997[8]	157	R, DB, PC	Iceland	25	NR	NR	29	18	NR	NR	25	17
Nicotine Tablet												
Shiffman 2002 i*[9]	458	R, DB, PC, MC	England & USA	17	NR	NR	24	14	NR	NR	18	10
Shiffman 2002 ii*[9]	451	R, DB, PC, MC	England & USA	27	NR	NR	24	10	NR	NR	15	6
Glover 2002 ii*[10]	158	R, DB, PC	USA	29	NR	NR	NR	NR	NR	NR	19	9
Wallström 2000 I*[11]	105	R, DB, PC	Sweden	20	NR	NR	34	20	NR	NR	29	20
Wallström 2000 ii*[11]	142	R, DB, PC	Sweden	20	NR	NR	33	17	NR	NR	16	13
Glover 2002 i*[10]	83	R, DB, PC	USA	29	NR	NR	21	13	NR	NR	17	12

CPD = cigarettes per day, R = randomized, DB = double-blind, PC = placebo controlled, MC = multi-center, NR = not reported.
References appear on the next page.
*The RCTs by Shiffman, Glover, and Wallstrom stratified randomization based on level of nicotine dependence; nicotine table was thus compared with placebo in patients with low (ii) and high (i) nicotine dependence, where nicotine dependence was defined by number of CPD.

References to Appendix 5 (page 2 of 2)

1. Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. *JAMA* 1993;269:1268-71.
2. Hjalmarson A, Nilsson F, Sjostrom L, et al. The nicotine inhaler in smoking cessation. *Arch Intern Med* 1997;157:1721-8.
3. Schneider NG, Olmstead R, Nilsson F, et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. *Addiction* 1996;91:1293-306.
4. Leischow SJ, Nilsson F, Franzon M, et al. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. *Am J Health Behav* 1996;20:364-71.
5. Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. *Addiction* 1995;90:1671-82.
6. Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. *Arch Intern Med* 1994;154:2567-72.
7. Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. *Lancet* 1992;340:324-9.
8. Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. *Eur Respir J* 1997;10:1585-90.
9. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. *Arch Intern Med* 2002;162:1267-76.
10. Glover ED, Glover PN, Franzon M, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. *Nicotine Tob Res* 2002;4:441-50.
11. Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction* 2000;95:1161-71.